1500 Participants Needed

AI Detection for Cardiovascular Disease Prevention

(AI INFORM Trial)

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Brigham and Women's Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if AI can identify coronary artery calcifications (CAC) on chest CT scans to help doctors start or adjust treatments that prevent heart problems. The AI tool, Nanox.AI Coronary Artery Calcification Assessment, analyzes CT scans and informs doctors about the presence of CAC, potentially improving preventive care. Participants should have had a chest CT scan in the last three years and should not have a history of heart disease or cancer. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance heart disease prevention strategies.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this AI platform is safe for cardiovascular disease prevention?

Research has shown that the Nanox.AI Coronary Artery Calcification Assessment helps identify heart disease risks by examining chest CT scans. Although the safety of this AI tool hasn't been tested on people like a new drug, it uses existing CT scans and doesn't introduce new physical risks to patients.

Nanox.AI's system has detected heart disease risks in many patients without any reported negative effects from the AI itself. The technology analyzes scan images and provides information to doctors, resulting in no additional side effects from using this software.12345

Why are researchers excited about this trial?

Researchers are excited about the AI Detection for Cardiovascular Disease Prevention trial because it uses cutting-edge AI technology to identify coronary artery calcification from chest CT scans. Unlike traditional methods that rely on manual interpretation by radiologists, this AI-based approach promises faster and potentially more accurate detection, helping doctors catch early signs of heart disease sooner. This could lead to timely interventions and personalized treatment plans, ultimately aiming to improve patient outcomes by preventing the progression of cardiovascular disease.

What evidence suggests that this AI platform is effective for detecting coronary artery calcifications?

Studies have shown that the Nanox.AI platform effectively detects calcium buildup in the heart's arteries, an early sign of heart disease. Research indicates that this AI tool identifies moderate to severe levels of this buildup in about 58% of patients. In this trial, one group will receive notification of coronary artery calcification detected by the AI, enabling doctors to start preventive treatments sooner, which may lead to better health outcomes. The other group will not receive notification. The AI technology not only finds these calcium buildups but also measures them, providing a detailed view of heart health risk.13467

Are You a Good Fit for This Trial?

This trial is for individuals aged 40-75 who've had a chest CT scan in the last 3 years and have no history of coronary artery disease, cancer, or any other life-limiting conditions. It's aimed at enhancing cardiovascular disease prevention.

Inclusion Criteria

I am between 40-75 years old and had a chest CT scan in the last 3 years.

Exclusion Criteria

I do not have any other condition that could shorten my life.
I have had heart disease related to my arteries.
I have had cancer before.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Notification or non-notification of coronary artery calcification detected by AI, followed by recommendation or non-recommendation of preventive therapy

6 months

Follow-up

Participants are monitored for changes in LDL-C, initiation or intensification of preventive therapies, and occurrence of cardiovascular events

12 months

What Are the Treatments Tested in This Trial?

Interventions

  • Nanox.AI Coronary Artery Calcification Assessment
Trial Overview The AI INFORM study is testing if notifying clinicians about the presence and amount of calcium buildup in arteries using an AI tool (Nanox.AI) leads to better preventive care. This involves analyzing past chest CT scans without contrast.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Notification of Coronary Artery CalcificationExperimental Treatment1 Intervention
Group II: Non-notification of Coronary Artery CalcificationActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Brigham and Women's Hospital

Lead Sponsor

Trials
1,694
Recruited
14,790,000+

Nano-X Imaging Limited

Collaborator

Trials
1
Recruited
1,500+

Published Research Related to This Trial

In a study involving 25 patients, the reliability of scoring coronary artery calcium burden using CT scans showed significant interobserver and intraobserver disagreements, particularly on small lesions.
Despite these disagreements, the impact on the overall measures of calcium burden (calcium score, number of calcified lesions, and calcified area) was negligible, suggesting that multiple observers scoring the same CT exam may not be necessary.
Detection of heart calcification with electron beam CT: interobserver and intraobserver reliability for scoring quantification.Kaufmann, RB., Sheedy, PF., Breen, JF., et al.[2016]
A fully automated AI model for scoring coronary artery calcium (CAC) demonstrated high accuracy, correlating strongly with manual assessments, with a Spearman's correlation of 0.90 and an intraclass correlation coefficient of 0.98 based on 1849 cardiac CT scans.
The AI model was able to classify 89% of scans into the same risk categories as human experts, while significantly reducing analysis time to an average of just 13.1 seconds per scan, suggesting it could enhance clinical workflow efficiency.
Evaluation of an artificial intelligence coronary artery calcium scoring model from computed tomography.Ihdayhid, AR., Lan, NSR., Williams, M., et al.[2023]
A deep learning system was developed to automatically quantify coronary artery calcium from routine CT scans, demonstrating strong predictive power for cardiovascular events in a study of 20,084 individuals across various cohorts.
The automated scoring system showed high correlation with manual quantification and robust reliability, suggesting it could effectively enhance clinical practice by streamlining the assessment of cardiovascular risk.
Deep convolutional neural networks to predict cardiovascular risk from computed tomography.Zeleznik, R., Foldyna, B., Eslami, P., et al.[2022]

Citations

AI Cardiac Solution - NanoxNanox.AI HealthCCSng algorithm identified moderate to severe levels of coronary artery calcium (CAC) in 58% of patients. Watch now. Close. Article. Cardiac ...
Innovative Data Featuring Nanox AI Cardiac Solution ...In a study conducted by Brigham & Women's Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients.
Nanox AI Cardiac Solution HealthCCSngNanox AI detects coronary artery calcification (CAC) to help identify patients at risk of coronary artery disease.
Using Artificial Intelligence to Semi-Quantitate Coronary ...Artificial intelligence (AI) algorithms can help detect and quantify CAC/ASCVD which can lead to early treatment and improved outcomes.
August 19, 2024 Nano-X AI Ltd. Neta Sherman Associate VP ...The device generates an exact calcium score and a four coronary artery calcium detection category output representing the estimated quantity of.
6.nanox.visionnanox.vision/ai/
Nanox.AIAI's cardiac solution, Corewell Health significantly increased their ability to detect coronary calcification, identifying nearly 4,000 new patients in 2023 ...
Data Supporting Nanox.AI Cardiac Solution to Be ...Nanox AI's Cardiac Solution (HealthCCSng) utilizes medical imaging data from routine chest CT scans to automatically quantify coronary artery ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity